JNJ - Johnson & Johnson

NYSE - Nasdaq Real Time Price. Currency in USD
127.14
-0.66 (-0.52%)
As of 10:06AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close127.80
Open127.53
Bid127.09 x 800
Ask127.13 x 1100
Day's Range127.08 - 127.69
52 Week Range118.62 - 148.32
Volume599,320
Avg. Volume6,590,496
Market Cap341.009B
Beta0.54
PE Ratio (TTM)281.28
EPS (TTM)0.45
Earnings DateOct 16, 2018
Forward Dividend & Yield3.60 (2.86%)
Ex-Dividend Date2018-05-25
1y Target Est143.45
Trade prices are not sourced from all markets
  • US companies are shipping goods before they're hit with tariffs: report
    Fox Business Videos2 days ago

    US companies are shipping goods before they're hit with tariffs: report

    Burke Financial Strategies CEO John Burke on the reports that some U.S. companies are shipping goods overseas before they have to start paying tariffs. Burke also discussed how stocks have lagged behind earnings.

  • Motley Fool30 minutes ago

    Should Investors Be Worried About Netflix, United Health, or Johnson & Johnson?

    Wall Street's just dinged two of them and rewarded the third -- but Motley Fool analysts take a longer view.

  • ACCESSWIRE3 hours ago

    Free Research Report as Johnson & Johnson's Quarterly Earnings Advanced 14.75%

    LONDON, UK / ACCESSWIRE / July 19, 2018 / If you want access to our free earnings report on Johnson & Johnson (NYSE: JNJ) ("JNJ”"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=JNJ. The Company reported its financial results on July 17, 2018, for the second quarter of the fiscal year 2018, ended June 30, 2018. The Company surpassed analysts’ estimates for earnings and revenues in Q2 FY18.

  • InvestorPlace13 hours ago

    New Drugs and Expected Growth Could Trigger a Recovery for Celgene Stock

    Celgene (NASDAQ:CELG) continues to struggle. A series of self-inflicted wounds and a looming patent expiration plague the Summit, New Jersey-based firm. As a result, CELG stock has lost more than 40% of its value since its October 2017 high.

  • J&J's Darunavir-Based Single-Tablet HIV Regimen Gets FDA Nod
    Zacks16 hours ago

    J&J's Darunavir-Based Single-Tablet HIV Regimen Gets FDA Nod

    The FDA approves Johnson and Johnson's (JNJ) darunavir-based single-tablet regimen, Symtuza, for the treatment of type 1 HIV-1 in treatment-naive and certain virologically suppressed adults.

  • Healthcare ETFs in Focus Following JNJ Q2 Results
    Zacksyesterday

    Healthcare ETFs in Focus Following JNJ Q2 Results

    Investors should closely watch the movement of the Johnson & Johnson and keep a close eye on ETFs having double-digit allocation to this diversified drug maker.

  • Penn, Johnson & Johnson team up to accelerate innovation
    American City Business Journalsyesterday

    Penn, Johnson & Johnson team up to accelerate innovation

    The university and health care giant are creating a life sciences network hub called JPOD@Philadelphia at the Pennovation Center.

  • Stock Market News For Jul 18, 2018
    Zacksyesterday

    Stock Market News For Jul 18, 2018

    Markets closed sharply higher on Tuesday, led by a rally in tech stocks.

  • TheStreet.comyesterday

    Rewind: Why Jim Cramer Is Bullish on Johnson & Johnson Shares

    TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer is bullish on Johnson & Johnson shares.

  • Benzingayesterday

    Benzinga's Daily Biotech Pulse: Novartis Earnings, J&J's HIV Combo Clears FDA Hurdle, Cara To Offer Shares

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Stocks hitting 52-week highs on July 17) Avid Bioservices Inc (NASDAQ: CDMO )( reversed to a profit ...

  • ACCESSWIREyesterday

    Today's Research Reports on Stocks to Watch: Johnson & Johnson and Avid Bioservices

    NEW YORK, NY / ACCESSWIRE / July 18, 2018 / Johnson & Johnson saw a pop after announcing second quarter results and vowing to appeal a court order last week that ordered the company to pay a whopping $4.69 billion to nearly two dozen women who alleged the company's talc products contained asbestos and caused them to develop ovarian cancer. Shares of Avid Bioservices also saw big gains after announcing a new CFO. Johnson & Johnson shares saw a gain of 3.54% by the close on Tuesday on trading volume nearly double compared to usual.

  • See what the IHS Markit Score report has to say about Johnson & Johnson.
    Markityesterday

    See what the IHS Markit Score report has to say about Johnson & Johnson.

    This could indicate that investors who seek to profit from falling equity prices are not currently targeting JNJ. Over the last one-month, outflows of investor capital in ETFs holding JNJ totaled $1.74 billion.

  • J&J (JNJ) Faces $4.69 Billion Verdict in Talc Case (Revised)
    Zacksyesterday

    J&J (JNJ) Faces $4.69 Billion Verdict in Talc Case (Revised)

    A Missouri jury asked Johnson & Johnson (JNJ) to pay $4.69 billion in damages to 22 women and their families, who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.

  • Asian stocks rise as solid US performance lifts spirits
    Associated Pressyesterday

    Asian stocks rise as solid US performance lifts spirits

    SINGAPORE (AP) — Asian markets climbed higher on Wednesday as a sweep of positive news from Wall Street and beyond boosted confidence in the U.S. economy.

  • The Wall Street Journalyesterday

    [$$] Johnson & Johnson’s Pharma Business Fuels Sales Growth

    Strong sales of Johnson & Johnson’s cancer drugs and other medicines helped boost the company’s revenue and earnings for the latest quarter, but the health-products giant’s U.S. consumer business continued to struggle. Sales in the pharmaceuticals unit rose 19.9% globally, the largest increase among J&J segments. Cancer-drug sales rose 42.2%, helped by big gains for the Zytiga prostate-cancer drug and Darzalex, a blood-cancer treatment. J&J’s pharmaceutical sales topped analysts’ expectations despite what executives said was a continued decline in average net U.S. pricing after discounts and rebates.

  • Novartis (NVS) Stock Flat Ahead of Earnings: What To Watch
    Zacksyesterday

    Novartis (NVS) Stock Flat Ahead of Earnings: What To Watch

    Shares of Novartis (NVS) added just 0.14% during regular hours Tuesday, the last day of trading before the pharma giant releases its latest quarterly earnings report. Here's what to expect tomorrow morning.

  • What's Behind Johnson & Johnson's Double-Digit Growth?
    Motley Fool2 days ago

    What's Behind Johnson & Johnson's Double-Digit Growth?

    Currency and acquisition tailwinds aside, the company has a slate of fast-growing drugs in its quiver.

  • TheStreet.com2 days ago

    Jim Cramer: A Pretty Wild Rally In Three Oppositional Groups

    You combine a Fed Chairman who doesn't want to throw us into a recession, which has suddenly become a big worry, with the absence of negative trade news and you get a pretty wild rally in not two but three oppositional groups, something that's not supposed to be happening and historically almost never does. First, let's take the camp that says forget what the Fed says about economic growth, the Treasury yield curve is almost inverted and that means a recession must occur.

  • British pharma company Eusa set to unveil deal with giant Johnson & Johnson
    The Telegraph2 days ago

    British pharma company Eusa set to unveil deal with giant Johnson & Johnson

    British pharma company Eusa set to unveil deal with giant Johnson & Johnson

  • What Happened in the Stock Market Today
    Motley Fool2 days ago

    What Happened in the Stock Market Today

    On a day stocks climbed following optimistic comments by the chairman of the Federal Reserve, Netflix reported disappointing subscriber additions, and Johnson & Johnson rose on strong pharmaceuticals sales.

  • Barrons.com2 days ago

    After the Bell: Dow Rises 56 Points as Stocks Keep Chugging Higher

    Stocks notched another day of gains on Tuesday, on a day when there was little in the way of market-moving news. The Dow Jones Industrial Average gained 55.53 points, or 0.22%, to 25,119.89, while the S&P 500 is up 11.12 points, or 0.40%, to 2809.55 and the Nasdaq Composite added 49.40 points, or 0.63%, to 7855.12. Part of it may have been a "no news is good news," sort of mentality, as Federal Reserve Chief Jerome Powell's dry testimony before the Senate Banking Committee seemed to indicate that the Central Bank was committed to staying the course and markets largely shrugged off earnings reports on a relatively quiet day.

  • Thomson Reuters StreetEvents2 days ago

    Edited Transcript of JNJ earnings conference call or presentation 17-Jul-18 12:30pm GMT

    Q2 2018 Johnson & Johnson Earnings Call

  • Moody's2 days ago

    MedPlast Holdings, Inc. -- Moody's assigns B2 CFR to MedPlast Holdings, Inc.

    Rating Action: Moody's assigns B2 CFR to MedPlast Holdings, Inc. New York, July 17, 2018 -- Moody's Investors Service ("Moody's) assigned a B2 Corporate Family Rating (CFR) and B2-PD Probability of Default Rating to MedPlast Holdings, Inc. ("MedPlast"). Moody's also assigned a B1 rating to the company's first lien credit facilities comprised of a $70 million revolving credit facility and a $500 million first lien term loan and a Caa1 rating to the company's $225 million second lien term loan.

  • Associated Press2 days ago

    Johnson & Johnson climbs while Netflix and UnitedHealth slip

    Stocks that moved substantially or traded heavily Tuesday: Netflix Inc., down $21 to $379.48 The streaming video company's second-quarter subscriber gains were weaker than analysts expected. Johnson & ...

  • Reuters2 days ago

    US STOCKS-Wall St climbs on Powell comments, earnings

    Wall Street stocks rose on Tuesday, with the Dow Jones Industrial Average posting its fourth consecutive session of gains after Federal Reserve Chairman Jerome Powell expressed an optimistic U.S. economic ...